March 09, 2026
DurAVR® THV Retrospective Analysis
At the CRT conference, on behalf of Dr. Rishi Puri, Dr. Jeffrey Popma presented a new retrospective analysis comparing DurAVR® THV vs. Edwards Sapien 3.
The aim of the analysis was to compare 30-day hemodynamic and clinical outcomes of DurAVR® THV vs. Sapien 3 in small aortic annuli (area ≤ 430 mm2). Inverse probability of treatment weighting was used to account for baseline differences. The analysis shows:
- DurAVR® THV demonstrated favorable hemodynamics with significantly lower mean gradients, larger EOAs, and higher DVI compared to Sapien 3.
- DurAVR® THV was associated with a significantly lower frequency of patient-prosthesis mismatch (PPM), with 98.5% freedom from moderate or severe PPM.
- 30-day safety event rates were comparable between DurAVR® THV and Sapien 3.